Biologics based on the structure of fibroblast growth factor (FGF) 19 and 21 show strong beneficial effects in the treatment of metabolic dysfunction–associated steatotic liver disease (MASLD), including compensated cirrhosis. The gene discussed is FGF19; the disease is Cirrhosis.